GlucoTrack, Inc.(GCTK)Earnings, Financials & Key Ratios

GCTK•NASDAQ

$0.36

Price updated Jul 7, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustryPatient monitoring and respiratory care

AboutGlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.Show more

Revenue$0
EBITDA-$16M-10.6%
Net Income-$19M+14.2%
EPS (Diluted)-21.56-135.5%
ROE-685.57%

GCTK Price & Volume

GlucoTrack, Inc. (GCTK) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Threaten Clinical Development Runway

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Clinical trial funding shortfall

Key Thesis Takeaways

GlucoTrack remains in a precarious pre-revenue stage, with its entire financial profile dominated by $2.1 million in quarterly R&D expenditures aimed at developing an implantable glucose monitoring system.
The company's reliance on equity-based incentives, such as the $61,000 in stock-based compensation reported in 2026Q1, highlights a desperate attempt to preserve cash amid a lack of commercial scale.
Investors should remain cautious as the firm's negative equity position of $851,000 and accelerating cash burn suggest a high probability of near-term dilutive financing requirements.

Verdict Logic

the company's negative shareholders' equity of $851,000 and the absence of commercial revenue suggest that the current capital structure is unsustainable without significant future dilution.

GCTK Growth Metrics

GlucoTrack, Inc. (GCTK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM36.28%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM93.46%

Return on Capital

10 Years29.02%

5 Years-251.69%

3 Years-357.68%

Last Year-416.73%

Peers Comparison

Key metrics vs top competitors for GlucoTrack, Inc. (GCTK)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
GCTKGlucoTrack, Inc.Current	$0.36	$204.28K	-0.02	—	—	-685.57%	—
DXCMDexCom, Inc.	$73.57	$28.39B	35.20	15.6%	19.31%	33.83%	—
PODDInsulet Corporation	$161.55	$11.34B	46.42	30.73%	10.44%	21.38%	—
TNDMTandem Diabetes Care, Inc.	$15.43	$1.06B	-5.08	7.93%	-9.2%	-68.29%	—
SENSSenseonics Holdings, Inc.	$5.33	$222.76M	-3.21	56.89%	-214.16%	-130%	—
NXTCNextCure, Inc.	$1.78	$4.77M	-0.09	—	—	-186.96%	—